論文 - 畠山 真吾
-
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.
Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 139 - 145 2022年03月
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C
BJUI compass 3 ( 2 ) 154 - 161 2022年03月
-
Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.
Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Okuyama Y, Kojima Y, Noro D, Tokui N, Okamoto T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 146 - 153 2022年03月
-
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M, Japan Urological Oncology Group
Urologic oncology 40 ( 3 ) 107.e1 - 107.e9 2022年03月
-
Effect of advanced glycation end products on nocturia or sleep disorders: A longitudinal study.
Konishi S, Hatakeyama S, Imai A, Okita K, Kido K, Ozaki Y, Uemura N, Iwane T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 162 - 168 2022年03月
-
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T
World journal of urology 2022年02月
-
Management of prostate cancer in older patients.
Narita S, Hatakeyama S, Sakamoto S, Kato T, Inokuchi J, Matsui Y, Kitamura H, Nishiyama H, Habuchi T
2022年02月
-
Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Noro D, Togashi K, Yoneyama T, Ohyama C.
International journal of urology 2022年02月
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C
Urologic oncology 40 ( 2 ) 64.e1 - 64.e8 2022年02月
-
Butyrylcholinesterase level as an independent prognostic factor for overall survival in patients on maintenance hemodialysis: a single-center retrospective study.
Fukushi K, Okamoto T, Ozaki Y, Ozaki K, Sasaki D, Miura Y, Okuyama Y, Tanaka Y, Imanishi K, Hatakeyama S, Saitoh F, Ohyama C
Clinical and experimental nephrology 26 ( 2 ) 190 - 197 2022年02月
-
Cohort profile: Alliance for Quality Assessment in Healthcare-Dialysis (AQuAH-D) prospective cohort study of patients on haemodialysis in Japan.
BMJ Open 2022年01月
-
The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.
Okuyama Y, Okamoto T, Sasaki D, Ozaki K, Songee J, Hatakeyama S, Mikami T, Ohyama C
International urology and nephrology 54 ( 1 ) 9 - 16 2022年01月
-
Editorial Comment to A case of miliary tuberculosis following transurethral surgery and prostate biopsy after intravesical bacillus Calmette-Guerin immunotherapy.
Hatakeyama S, Ohyama C
IJU case reports 5 ( 1 ) 47 - 48 2022年01月
-
CRPCにおけるリキッドバイオプシー 糖鎖とcfDNAを用いた検討
畠山 真吾, 米山 徹, 濱野 逸人, 久保田 優花, 松本 哲平, 成田 拓磨, 藤田 尚紀, 岡本 哲平, 山本 勇人, 米山 高弘, 橋本 安弘, 大山 力
泌尿器科 15 ( 1 ) 83 - 91 2022年01月
-
Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer
畠山 真吾, 大山 力
International Journal of Urology - ( 5 ) 420 - 421 2022年
-
腎移植後症例に対するダプロデュスタット12か月投与における有効性と安全性
村上 礼一, 日村 美玲, 奈川 大輝, 金城 育代, 藤田 雄, 島田 美智子, 富田 泰史, 畠山 真吾, 米山 高弘, 橋本 安弘, 大山 力
移植 57 ( Supplement ) s289_1 - s289_1 2022年
-
Relationship between the cross-sectional area of the lumbar dural sac and lower urinary tract symptoms: A population-based cross-sectional study.
Oyama T, Wada K, Koyama K, Kumagai G, Tanaka S, Asari T, Imai A, Okamoto T, Hatakeyama S, Jung S, Sugimura Y, Ohyama C, Ishibashi Y
PloS one 17 ( 8 ) e0271479 2022年
-
Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma
畠山 真吾, 米山 徹, 大山 力
International Journal of Urology - ( 7 ) 733 - 739 2022年
-
The effect of number of treatment cycles of platinum-based first-line chemotherapy on maximum radiological response in patients with advanced urothelial carcinoma.
Okita K, Hatakeyama S, Hagiwara K, Suzuki Y, Tanaka T, Noro D, Tokui N, Fujita N, Konishi S, Okamoto T, Yoneyama T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
Urologic oncology 39 ( 12 ) 832.e17 - 832.e23 2021年12月
-
Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
Yoneyama T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, Hatakeyama S, Narita T, Kodama H, Momota M, Ito H, Narita S, Tsushima F, Mitsuzuka K, Yoneyama T, Hashimoto Y, Duivenvoorden W, Pinthus JH, Kakeda S, Ito A, Tsuchiya N, Habuchi T, Ohyama C
The Prostate 81 ( 16 ) 1411 - 1427 2021年12月